Literature DB >> 25690668

von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo.

O Rawley1, J M O'Sullivan, A Chion, S Keyes, M Lavin, N van Rooijen, T M Brophy, P Fallon, R J S Preston, J S O'Donnell.   

Abstract

BACKGROUND: Enhanced von Willebrand factor (VWF) clearance is important in the etiology of type 1 and type 2 von Willebrand disease (VWD). More than 20 different VWF point mutations have already been reported in patients with enhanced clearance. These include the VWD-Vicenza variant, which is characterized by an Arg1205His substitution in the VWF D3 domain. Critically, however, the molecular mechanisms through which single amino acid substitutions in VWF result in enhanced clearance of this complex multimeric glycoprotein have not been defined.
OBJECTIVES: In this study, we have investigated the biological basis underlying the enhanced clearance of the VWF-R1205H variant.
METHODS: Using VWF(-/-) mice, in vivo clearance rates were determined for a series of full-length and truncated recombinant VWF variants. In addition, the role of macrophages in modulating enhanced VWD-Vicenza clearance was investigated using clodronate liposome administration.
RESULTS: Our findings demonstrate that substitutions of R1205 with histidine, cysteine or serine all result in markedly reduced survival of full-length recombinant VWF. Importantly, D'A3 fragments containing these same R1205 substitutions also demonstrated significantly enhanced clearance. In contrast to the reduced in vivo survival observed with R1205H, clearance of R1204H was not enhanced. Recent studies have demonstrated that hepatic and splenic macrophages play key roles in regulating VWF clearance. Importantly, macrophage-depletion also served to markedly attenuate the enhanced clearance phenotypes associated with VWF-R1205H, VWF-R1205S and VWF-R1205C.
CONCLUSIONS: Collectively, these novel findings demonstrate a specific and critical role for the R1205 residue in modulating macrophage-mediated clearance of VWF in vivo.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  glycosylation; metabolic clearance rate; von Willebrand disease, Type 1; von Willebrand disease, Type 2; von Willebrand factor

Mesh:

Substances:

Year:  2015        PMID: 25690668     DOI: 10.1111/jth.12875

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

Authors:  Ergul Berber; Mehmet Ozbil; Christine Brown; Zafer Baslar; S Hande Caglayan; David Lillicrap
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

2.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

3.  The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.

Authors:  Laura L Swystun; Jesse D Lai; Colleen Notley; Ilinca Georgescu; A Simonne Paine; Jeff Mewburn; Kate Nesbitt; Kai Schledzewski; Cyrill Géraud; Julia Kzhyshkowska; Sergij Goerdt; Wilma Hopman; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

Review 4.  New treatment approaches to von Willebrand disease.

Authors:  Michelle Lavin; James S O'Donnell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

Review 6.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

7.  Endocytosis by macrophages: interplay of macrophage scavenger receptor-1 and LDL receptor-related protein-1.

Authors:  Eelke P Béguin; Małgorzata A Przeradzka; Esmée F J Janssen; Henriët Meems; Magdalena Sedek; Carmen van der Zwaan; Koen Mertens; Maartje van den Biggelaar; Alexander B Meijer; Marjon J Mourik
Journal:  Haematologica       Date:  2019-06-27       Impact factor: 9.941

Review 8.  Low VWF: insights into pathogenesis, diagnosis, and clinical management.

Authors:  James S O'Donnell
Journal:  Blood Adv       Date:  2020-07-14

Review 9.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

10.  Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance.

Authors:  Soracha E Ward; Jamie M O'Sullivan; Alan B Moran; Daniel I R Spencer; Richard A Gardner; Jyotika Sharma; Judicael Fazavana; Marco Monopoli; Thomas A J McKinnon; Alain Chion; Sandra Haberichter; James S O'Donnell
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.